Literature DB >> 29366750

Defining the molecular signatures of human right heart failure.

Jordan L Williams1, Omer Cavus2, Emefah C Loccoh2, Sara Adelman2, John C Daugherty1, Sakima A Smith2, Benjamin Canan1, Paul M L Janssen1, Sara Koenig1, Crystal F Kline1, Peter J Mohler3, Elisa A Bradley4.   

Abstract

AIMS: Right ventricular failure (RVF) varies significantly from the more common left ventricular failure (LVF). This study was undertaken to determine potential molecular pathways that are important in human right ventricular (RV) function and may mediate RVF.
MATERIALS AND METHODS: We analyzed mRNA of human non-failing LV and RV samples and RVF samples from patients with pulmonary arterial hypertension (PAH), and post-LVAD implantation. We then performed transcript analysis to determine differential expression of genes in the human heart samples. Immunoblot quantification was performed followed by analysis of non-failing and failing phenotypes. KEY
FINDINGS: Inflammatory pathways were more commonly dysregulated in RV tissue (both non-failing and failing phenotypes). In non-failing human RV tissue we found important differences in expression of FIGF, TRAPPAC, and CTGF suggesting that regulation of normal RV and LV function are not the same. In failing RV tissue, FBN2, CTGF, SMOC2, and TRAPP6AC were differentially expressed, and are potential targets for further study. SIGNIFICANCE: This work provides some of the first analyses of the molecular heterogeneity between human RV and LV tissue, as well as key differences in human disease (RVF secondary to pulmonary hypertension and LVAD mediated RVF). Our transcriptional data indicated that inflammatory pathways may be more important in RV tissue, and changes in FIGF and CTGF supported this hypothesis. In PAH RV failure samples, upregulation of FBN2 and CTGF further reinforced the potential significance that altered remodeling and inflammation play in normal RV function and failure.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Molecular mechanisms; Pulmonary hypertension; Right heart failure; Right ventricular failure

Mesh:

Substances:

Year:  2018        PMID: 29366750      PMCID: PMC6310003          DOI: 10.1016/j.lfs.2018.01.021

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  61 in total

Review 1.  Mechanisms and models in heart failure: A combinatorial approach.

Authors:  D L Mann
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

2.  Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy.

Authors:  D Abraham; R Hofbauer; R Schäfer; R Blumer; P Paulus; A Miksovsky; H Traxler; A Kocher; S Aharinejad
Journal:  Circ Res       Date:  2000-10-13       Impact factor: 17.367

3.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

4.  CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.

Authors:  M M Chen; A Lam; J A Abraham; G F Schreiner; A H Joly
Journal:  J Mol Cell Cardiol       Date:  2000-10       Impact factor: 5.000

5.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

6.  Correlation between protein and mRNA abundance in yeast.

Authors:  S P Gygi; Y Rochon; B R Franza; R Aebersold
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

7.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

8.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats.

Authors:  Mohammed Shakil Ahmed; Erik Øie; Leif Erik Vinge; Arne Yndestad; Geir Øystein Andersen; Yvonne Andersson; Toril Attramadal; Håvard Attramadal
Journal:  J Mol Cell Cardiol       Date:  2004-03       Impact factor: 5.000

View more
  9 in total

1.  WIPI1 is a conserved mediator of right ventricular failure.

Authors:  Christos Tzimas; Christoph D Rau; Petra E Buergisser; Gaston Jean-Louis; Katherine Lee; Jeffrey Chukwuneke; Wen Dun; Yibin Wang; Emily J Tsai
Journal:  JCI Insight       Date:  2019-04-25

2.  Molecular signaling pathways in right ventricular impairment of adult patients after tetralogy of Fallot repair.

Authors:  Kathrin Pollmann; Sarala Raj Murthi; Damir Kračun; Thomas Schwarzmayr; Andreas Petry; Julie Cleuziou; Jürgen Hörer; Mathieu Klop; Peter Ewert; Agnes Görlach; Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

3.  Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.

Authors:  Varina R Clark; Somanshu Banerjee; John F Park; Jason Hong; Asif Razee; Tiffany Williams; Gregory Fishbein; Lou Saddic; Soban Umar
Journal:  Circ Heart Fail       Date:  2021-02-05       Impact factor: 10.447

Review 4.  Cellular and molecular pathobiology of heart failure with preserved ejection fraction.

Authors:  Sumita Mishra; David A Kass
Journal:  Nat Rev Cardiol       Date:  2021-01-11       Impact factor: 49.421

5.  Weighted correlation network bioinformatics uncovers a key molecular biosignature driving the left-sided heart failure.

Authors:  Jiamin Zhou; Wei Zhang; Chunying Wei; Zhiliang Zhang; Dasong Yi; Xiaoping Peng; Jingtian Peng; Ran Yin; Zeqi Zheng; Hongmei Qi; Yunfeng Wei; Tong Wen
Journal:  BMC Med Genomics       Date:  2020-07-03       Impact factor: 3.063

6.  Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent bone loss.

Authors:  Supawich Morkmued; François Clauss; Brigitte Schuhbaur; Valérie Fraulob; Eric Mathieu; Joseph Hemmerlé; Hans Clevers; Bon-Kyoung Koo; Pascal Dollé; Agnès Bloch-Zupan; Karen Niederreither
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

7.  Noncanonical WNT Activation in Human Right Ventricular Heart Failure.

Authors:  Jonathan J Edwards; Jeffrey Brandimarto; Dong-Qing Hu; Sunhye Jeong; Nora Yucel; Li Li; Kenneth C Bedi; Shogo Wada; Danielle Murashige; Hyun Tae V Hwang; Mingming Zhao; Kenneth B Margulies; Daniel Bernstein; Sushma Reddy; Zoltan Arany
Journal:  Front Cardiovasc Med       Date:  2020-10-07

8.  VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium.

Authors:  Tongyu Wang; Jiahu Tian; Yuanzhe Jin
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

Review 9.  Right ventricular phenotype, function, and failure: a journey from evolution to clinics.

Authors:  Yannick J H J Taverne; Amir Sadeghi; Beatrijs Bartelds; Ad J J C Bogers; Daphne Merkus
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.